Latest Market Launch News

Light & Wonder, Inc. posted robust Q3 2025 results, driven by strong gaming operations and record iGaming revenue, while advancing its transition to a sole ASX listing.

Bioxyne Limited, through its subsidiary Breathe Life Sciences, has inked an exclusive deal to import, manufacture, and distribute Curaleaf’s Que Medical Inhalation Device in Australia, with a nationwide launch set for November 2025.

Cleo Diagnostics has secured positive FDA feedback and nearly 1,600 biobank samples, accelerating its ovarian cancer blood test development ahead of a planned 2026 U.S. market entry.

HITIQ Ltd has secured a landmark order for its PROTEQT™ mouthguards at the Winter Olympics and launched in the UK consumer market, while advancing global validation and raising over A$2 million in capital.

Firebrick Pharma is set to expand its Nasodine product line with the launch of a new throat spray, targeting export markets starting November 2025, beginning with Singapore.

Cleo Diagnostics has successfully completed Stage 1 of the Medical Device Single Audit Program, marking a significant step toward FDA submission and global commercialisation of its ovarian cancer test.

Urbanise.com Limited reported a 12.4% revenue increase in Q1 FY2026, driven by its NAB partnership, while investing heavily in its Data and Payments Integration Services (DPIS) with expected cash outflows through FY2026.

Atomo Diagnostics reported strong commercial momentum in Q1 FY26, highlighted by a key FDA submission for its FebriDx test and a successful capital raise of $1.3 million. The company also showcased promising clinical data for its Active Syphilis test and expanded its HIV Self-Test distribution channels.

Adslot Ltd reports solid progress in Q1 FY26, highlighting growth in its StoreFront and Marketplace platforms alongside a successful $989,000 capital raise to fuel expansion.

LTR Pharma has made significant strides towards its US market debut with ROXUS, bolstered by expert appointments and peer-reviewed clinical data validating its rapid-onset ED treatments.

IODM Limited has reported a record-breaking first quarter for FY26, with cash receipts soaring 76% year-on-year, driven predominantly by explosive growth in its UK Education segment. The company also made strategic advances in North America and Japan, setting the stage for broader global expansion.

Firebrick Pharma reports a $1.94 million cash reserve after a $1.4 million placement, supporting expanded Nasodine sales across Southeast Asia and the US. Board changes and increased operational costs mark a pivotal quarter for the pharmaceutical innovator.